

## A review of Vitamin D effects on common respiratory diseases: Asthma, chronic obstructive pulmonary disease, and tuberculosis

[Mohammad Esmaeil Hejazi](#),<sup>1</sup> [Faezeh Modarresi-Ghazani](#),<sup>2</sup> and [Taher Entezari-Maleki](#)<sup>2</sup>

<sup>1</sup>Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

<sup>2</sup>Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

**Corresponding author:** Dr. Taher Entezari-Maleki, E-mail: [tentezari@gmail.com](mailto:tentezari@gmail.com)

Received 2015 May; Accepted 2015 Aug.

**Copyright** : © Journal of Research in Pharmacy Practice

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

### Abstract

Despite the classic role of Vitamin D in skeletal health, new aspects of Vitamin D have been discovered in tissues and organs other than bones. Epidemiological and observational studies demonstrate a link between Vitamin D deficiency and risk of developing respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD), and tuberculosis (TB). To review the literature, we searched the terms “Vitamin D” (using the set operator) and “asthma,” “COPD” and “TB” in electronic databases, including PubMed/MEDLINE, Scopus, and Google Scholar until July 2015. Non-English articles or articles with unavailable full text were excluded. Both *in vivo* and *in vitro* studies were included. All the reviewed articles state that Vitamin D deficiency is very common among patients with respiratory diseases. The present data regarding Vitamin D and asthma is still controversial, but data about COPD and TB are more encouraging. The relevant studies have been conducted in different populations therefore it is not particularly possible to compare the data due to genetic variations. In order to point out a role for Vitamin D, large clinical trials with Vitamin D deficient subjects and sufficient Vitamin D supplementation are needed.

**Keywords:** Asthma, chronic obstructive pulmonary diseases, respiratory diseases, tuberculosis, Vitamin D

### INTRODUCTION

Despite the classic role of Vitamin D in skeletal health, new aspects of Vitamin D have been discovered in tissues and organs other than bones. Epidemiological and observational studies demonstrate a link between Vitamin D deficiency and risk of developing respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD), and tuberculosis (TB).

The topics “Vitamin D” (using the set operator) and “asthma,” “COPDs” and “TB” were searched through the search engine in database such as PubMed/MEDLINE, Scopus, and Google Scholar until July 2015. Clinical trials and human studies only were included. Non-English articles or articles with unavailable full text were excluded. Both *in vivo* and *in vitro* studies were included. The search resulted in 46 articles about Vitamin D and asthma, 11 articles about Vitamin D and COPD, and 28 articles about Vitamin D and TB.

## VITAMIN D AND RESPIRATORY DISEASES

---

Vitamin D has major effects in the respiratory system as it can affect pulmonary cell biology as well as its immunity. To support this idea, high expression of CYP27B1, which forms the active Vitamin D has been observed in the epithelial cells of lungs.[1] Studies also indicate a high significance between Vitamin D receptor (VDR) polymorphism and lower respiratory tract infections.[2] Epidemiological studies demonstrate that suboptimal level of Vitamin D is associated with a number of lung disease[3] including viral respiratory infections,[4] chronic rhinitis, rhinosinusitis,[5] COPD,[6] asthma,[7,8] and TB.[9]

## ASTHMA

---

According to the Global Initiative for Asthma guidelines, asthma is a potentially serious chronic disease with symptoms such as wheezing, chest tightness, and cough. The interest to discover a relationship between asthma and Vitamin D was generated when observations indicated that Vitamin D deficiency and asthma have common risk factors including urban residence,[10,11] obesity,[12,13] and being African-American.[14,15] The beneficial effects of Vitamin D on asthma can be explained by several mechanisms. T-helper type 9 lymphocytes play an important role in the pathogenesis of asthma. Vitamin D can decrease inflammatory cytokines such as IL-9, IL-5, and IL-13 in these cells.[16] Steroid resistance is a major problem in the treatment of asthma. Vitamin D can overcome this resistance by generating IL-10-secreting regulatory T cells[17] and down-regulating the expression of FKN, a gene causing steroid resistance.[18] Even a combination of Vitamin D and dexamethasone were more effective in decreasing the inflammatory cytokines than dexamethasone alone.[16,19]

Vitamin D increases the expression of a peptide called cathelicidin which is a part of the innate immune system and an antimicrobial agent against *Mycobacterium tuberculosis* (MT), Gram-negative and Gram-positive bacteria, fungi, and viruses.[20] Maybe that is why Vitamin D deficiency can increase the risk of developing an infectious disease like influenza and influenza by itself can trigger asthma. Hyperplasia and excess proliferation of smooth muscle are important causes of chronic asthma and vascular endothelial growth factor, IL-6, and fibrinogen act as key factors in these processes. Vitamin D can down-regulate all of these factors[21] and give more time to the cells to repair DNA damage by preventing the cell from entering S phase.[22] Genes involved in Vitamin D pathways are associated with the pathogenesis of asthma, so Vitamin D and asthma may have a genomic-based relationship.[23] In animal studies reviewed, VDR-knockout mouse exhibited elevated levels of collagen deposition in airway tissue and pulmonary neutrophils, which increase hyperplasia in pulmonary tissues.[24] Vitamin D is also important in reducing airway inflammation, but this effect seems to be dependent on the baseline eosinophil levels.[25]

Several studies have investigated the relationship between maternal diet and risk of asthma.[26,27] It is also a fact that a maternal diet high in antioxidants and Vitamins D and E decreases the risk of childhood wheezing and asthma,[28,29,30,31,32] however one study did not find any evidence linking maternal diet and asthma in 5-year-old children except for apples and fish which have a reverse association with developing asthma.[33] An *in vitro* study by Miller *et al.* demonstrated that neonatal nasal airway epithelial which was exposed to the higher level of the maternal Vitamin D released higher IL-10 levels after exposure to tumor necrosis factor alpha (TNF- $\alpha$ ) or house dust mite which can be important in developing asthma later in life.[34] One study by Chiu *et al.*[38] among 164 mother-infant pairs in Taiwan reported that there is a significant reverse relationship between maternal Vitamin D levels and specific IgE antibodies against allergens before age 2. On the other hand, treatment with 25(OH)<sub>2</sub>D<sub>3</sub> has been able to significantly decrease TNF- $\alpha$  production and frequency of CD16-positive monocytes.[35] As revealed by another study, Vitamin D supplementation could also decrease pro-inflammatory cytokine such as IL-17 and increase CD38 releasing B cells.[36] The largest prospective cohort measuring Vitamin D levels in pregnant women and following up the offspring for 20–25 years reported that not only high maternal Vitamin D has no effect on allergic airway disease or lung function, it even increases the risk for allergic disease in offspring.[37]

Children born to Vitamin D deficient mothers were more likely to develop eczema and asthma at age 4. [38] Another interesting study regarding the genomic effect of Vitamin D on asthma reported that single-nucleotide polymorphisms in the Vitamin D hydroxylase enzyme gene are associated with asthma diagnosis in children. [39] There is an ongoing clinical trial which examines the effect of Vitamin D supplementation among healthy toddlers which will report whether or not Vitamin D can decrease upper respiratory infections and asthma exacerbations among these children, and the most importantly it will establish the optimal dose of Vitamin D which should be used as a supplement. [40]

Observational data suggest that Vitamin D insufficiency is common among asthmatic children in the USA. [41] Among Qatari children, Vitamin D deficiency was a strong predictor of asthma [42] and was negatively associated with markers of asthma severity and exacerbation severity in children. [43,44] One study including 100 children stated that 60,000 IU Vitamin D per month could significantly reduce the severity of asthma and help patients better control asthma. [45]

Correlation between asthma and Vitamin D deficiency has also been investigated in adults. According to the clinical trial Vitamin D deficiency impairs lung function; increases airway hyperresponsiveness and can decrease the response to glucocorticoids, [46] but later on the larger clinical trial stated the otherwise. According to this study which included asthmatic patients with Vitamin D deficiency, supplementation with 100,000 IU at first and then 4000 IU/day of Vitamin D had no effect in improving glucocorticoid response or asthma exacerbation. [47] Data from the Third National Health and Nutrition Examinations Survey, conducting a cross-sectional study, including 14,091 participants during 6 years, revealed a significant relationship among Vitamin D, mean forced expiratory volume (FEV), and forced vital capacity. [48] Another clinical trial among asthmatic patients in Iran which followed the patients for 24 weeks and supplemented the intervention group with 100,000 IU bolus intramuscular (IM) Vitamin D and 50,000 IU weekly oral Vitamin D found that intervention group had a significantly enhanced FEV1. [49] Reactive airway dysfunction syndrome is a condition similar to asthma but does not respond to conventional asthma treatment. Varney *et al.* could successfully treat a patient who had this syndrome with high-dose Vitamin D. [50] Finally, one cross-sectional study including 15,212 individuals during a 2-year follow-up found no association between Vitamin D insufficiency and risk of asthma. [51] Of the latest clinical trials regarding Vitamin D and asthma, Martineau *et al.* conducted the clinical trial based on 3 mg Vitamin D<sub>3</sub> supplementation for over a year. Participants included 250 adults with asthma, and 82% of them had Vitamin D insufficiency. According to the results, Vitamin D supplementation had no effect on the asthma exacerbation or viral upper respiratory infections. [52]

## CHRONIC OBSTRUCTIVE PULMONARY DISEASE

COPD is a progressive disease, characterized by irreversible airflow destruction. [53,54] It's one of the most common lung diseases. The main etiologic processes which are related to lung damages in COPD are inflammation, oxidative stress, and pulmonary protease-antiprotease imbalance. [54,55,56,57] It is accepted that the inflammation of the small airways plays the principal role in the pathogenesis of the disease. [54] Although COPD is considered as an "adult" disease, researchers are focusing on finding early life factors contributing to the disease. [58,59] Like asthma, Vitamin D could be one of these early life factors, affecting early lung development. There are currently no epidemiological data to indicate an association between childhood Vitamin D deficiency and COPD, but *in vivo* and *in vitro* studies suggest a strong role for Vitamin D in lung development. For example experiments in the developing rat lung indicate that presence of Vitamin D in alveolar type II cells can increase surfactant synthesis and regulate epithelial-mesenchymal interactions. [60,61] There is also one study that suggests among culture cells; cigarette smoke exposure has a direct effect on Vitamin D pathways. [62] The mechanism of Vitamin D on the improvement of COPD is unclear. However, evidence proved that it can regulate the activity of immune cells, [3] improve the strength of airway muscles, and modulate inflammatory responses. [63] In COPD

patients, there's a local down-regulation of Vitamin D signaling, which leads to an insufficient control of pro-inflammatory processes in the airways.[64]

According to recent findings, the prevalence of Vitamin D deficiency is between 33% and 77% among advanced COPD patients, which is significantly higher in COPD cases, compared with smokers without COPD.[6,65] Lower levels of Vitamin D in COPD may be explained with the reduction of cutaneous Vitamin D<sub>3</sub> production caused by smoking and limited sunlight exposure. Other mechanisms of Vitamin D deficiency could be reduced Vitamin D activation in liver and kidneys, increased Vitamin D sequestration in adipose tissue and decreased intestinal absorption.[55,66]

According to recent studies, there is a significant relationship between Vitamin D levels and lung function.[53,55] Research data indicated that serum 25(OH)D concentration is associated with the low FEV1 volume in patients with COPD.[67,68] In a prospective cohort study of 18,507 participants, the incidence risk of COPD was higher in the lower plasma 25(OH)D levels during the 20 years of follow-up.[69] In addition, recent findings demonstrated that serum level of 25(OH)D correlates with the severity of COPD[66] and affecting the severity of exacerbations.[70] However, it does not seem to be associated with the mortality rate in these patients.[71] Although baseline 25(OH)D levels are not predictive of acute COPD exacerbation.[72] Lehouck *et al.* reported that Vitamin D supplementation may reduce the COPD exacerbations in patients with severe deficiency.[73] Moreover, according to a pilot randomized trial, 2000 IU of daily Vitamin D for 6 weeks will increase serum 25(OH) D to a normal level in severe COPD patients.[74]

A recent cohort study of COPD cases demonstrated that serum 25(OH)D concentrations positively correlates with the maximal aerobic capacity (VO<sub>2</sub> peak) and carbon monoxide transfer, so the low levels of Vitamin D could reduce the exercise capacity in these cases.[75] These findings are confirmed by the results of a randomized trial, which reported that Vitamin D supplementation could significantly improve the inspiratory muscle strength and exercise capacity, during rehabilitation in COPD patients.[76]

According to molecular and animal experiments, Banerjee and Panettieri described the effects of Vitamin D on airway smooth muscle cells in a review study. It's demonstrated that Vitamin D stimulates the airway smooth muscle cells to express VDR, which modulates the cell proliferation and inflammatory mediators' secretion. In addition, it can regulate the inflammation, contraction, and remodeling in other cell types.[77]

Studies indicate a high prevalence of osteoporosis and osteopenia among COPD patients.[78] Duckers *et al.* reported that COPD patients are more affected with osteoporosis and osteopenia compared with other smokers,[79] it confirms the results of other studies, which found a relationship between bone mineral density, severity of COPD, and Vitamin D levels.[80,81]

Although the longitudinal studies have proven the relationship between the serum Vitamin D status and COPD, recent data may impose doubt on the results. A recent study of 12,041 patients through 1993–2008 found a statistically significant inverse association between Vitamin D status and COPD prevalence, but Vitamin D status didn't correlate to the incident COPD.[82]

Moreover, there has been an attention toward the role of the Vitamin D-binding protein (VDBP; or Gc-globulin) in COPD disease.[83] Studies found a higher level of VDBP in COPD patients.[84] VDBP is a serum protein which involves in neutrophil chemotaxis and macrophage activation, which are believed to be important in COPD pathogenesis. The major amount of circulating Vitamin D is attached to VDBP, which has a positive effect on Vitamin D uptake.

Pro-inflammatory cytokines can affect the transcription of Gc-globulin, which may act as an acute phase reactant. It also interacts with neutrophil elastase, which plays the important part in COPD pathogenesis.[85] Other polymorphisms of the VDBP (rs7041 T allele) correlated with low Vitamin D levels and exhibited an increased risk for COPD.[6]

## TUBERCULOSIS

Regardless of the success in the treatment of infectious diseases over the decades, TB remains one of the hardest infectious diseases to treat, due to an increasing rate of resistance to medication.[86] During the pre-antibiotic era, cod liver oil, a primary source of Vitamin D was used to treat TB, so the relationship between Vitamin D, and TB is not such a recent finding.[87]

People with TB infection are commonly involved with Vitamin D deficiency.[88] In fact, Vitamin D depletion could be a predictor of TB infections because of its essential functions in the immune system. 1,25-dihydroxy Vitamin D can effects MT by the production of the peptide called cathelicidin. Other than being an antiviral agent, cathelicidin has a direct antibacterial effect on MT.[89,90] The increased activation of toll-like receptor by Vitamin D also results in the production of defensin-2 and cathelicidin.[91] Vitamin D can induce autophagy of monocytes, as well as enhancing phagolysosome formation.[91,92] Furthermore, presence of Vitamin D is essential for interferon-gamma-mediated antimicrobial function of macrophages.[93] Another relevant role of Vitamin D in controlling TB could be its modulatory effect in T cell phenotype, balancing Th1, and Th2 responses.[94,95,96]

In attempt to find a role for Vitamin D in the treatment of TB, many studies have investigated the effect of Vitamin D supplementation on TB. The results of a meta-analysis including 531 participants reported that serum Vitamin D is reversely associated with risk of active TB.[97] One randomized clinical trial in Jakarta, supplementing TB patients with either 0.25 mg/day Vitamin D or placebo observed 100% sputum conversion in Vitamin D receiving comparing to 78.7% in placebo-receiving group.[98] However, another clinical trial including 365 patients with TB found no association between Vitamin D supplementation (100,000 IU in the start of TB therapy, 5 and 8 months later). According to the authors, these results could be due to the insufficient Vitamin D dose.[99] In a recent study, patients on supplementation with four doses of 2.5 mg Vitamin D displayed sputum clearance 1-week earlier than placebo, but this difference was not significant.[100] Another clinical trial comprising 259 TB patients received either 600,000 IU Vitamin D<sub>3</sub> IM or the matching placebo for 12 weeks. The results were favorable as Vitamin D group had the greater weight gain, smaller cavity size and decreased a number of pulmonary zones involved.[101] The most recent clinical trial with 2.5 mg Vitamin D at baseline and 2, 4, 6 weeks among TB patients indicate that this supplementation is unable to reduce time to sputum conversion.[102]

Interestingly among TB close contacts, a single-dose of 2.5 mg Vitamin D was able to enhance immunity response against MT.[103]

In additional, there is seasonality associated with TB incidence. In countries such as the UK, the incidence of TB is higher in spring, a season when serum Vitamin D level is low.[104,105,106] This seasonality has been observed in most of the countries including Europe,[107] South Africa,[108,109] and India.[110] One study by Strachan *et al.* among Asian immigrants in the UK indicated that a vegetarian diet, known to be low in Vitamin D, is a risk factor for development of TB, probably due to attenuated immune responses against MT.[111]

There is little information known about infants' immunity to TB regarding Vitamin D serum level, however one study reported 86% Vitamin D deficiency (below 20 nmol/ml) or insufficiency (below 75 nmol/ml) among children with active TB.[112]

Genetics are clearly relevant in the subject. Among Asians, those with the FokI FF genotype of VDR are the more susceptible to TB,[113] whereas the genotype of TaqI is a risk factor for developing TB among Gambian men.[114]

As a conclusion, administration of Vitamin D to patients with positive pulmonary TB who are taking anti-TB medication, benefited them by several means including shortened sputum conversion period, improved the inhibitory effect of treatment on monocyte count, inflammatory cytokines, chemokines, and Th1 cytokine response.[115]

## DISCUSSION

---

Of the trials reviewed about asthma, the Third National Health and Nutrition Examinations Survey reported the beneficial effects of Vitamin D on asthma,[48] but in contrast the other two large sample studies; the Korea National Health and Nutrition Examination Survey and offspring cohort reported no such a thing.[37,51] Comparing the results of these two studies may not be wise because they are conducted on two different populations, with highly possible genetic differences and lifestyle. Among other studies, none of them reported the possible interaction of age on Vitamin D and asthma relationship and the most of the trials did not equally distribute the patients according to their sex or had the insufficient sample size.[116] It is also essential to measure Vitamin D serum levels at least 2 or 3 times during the study to reassure the serum level is as required.

Data on Vitamin D and COPD are more promising because in the majority of the studies, Vitamin D was associated with better lung function and could ameliorate COPD. Due to the high rate of bone problems associated with COPD, supplementing Vitamin D in this patients and correcting its deficiency seems vital. On the hand, recent data indicates there are many polymorphisms in the VDR gene, but the effect of VDR gene polymorphisms on the risk of respiratory infections in patients with COPD is largely unknown. [117,118] There is a hypothesis that COPD patients may have different genes predisposing them to Vitamin D deficiency and therefore, certain genes might be involved in the pathogenesis of COPD regarding Vitamin D. As a result these genetic variations could be the cause of discrepancies in Vitamin D and COPD relationship.[6]

Much of our knowledge about Vitamin D and TB centers mostly on Vitamin D's antibacterial effect regarding both innate and adaptive immune responses, however, other aspects of Vitamin D on TB, including its effect on latent TB is not as much investigated.[119] Of the reviewed articles, the majority found a beneficial role for Vitamin D in TB, but one clinical trial did not.[102] Further studies are needed to be initiated to assess the use of Vitamin D as an adjunctive therapy in TB infections. Most of the trials have been conducted using highly effective anti-TB therapy in which Vitamin D's effect is more likely to be modest, so larger trials with bolus doses of Vitamin D are needed to fully detect its role on TB. Treatment with Vitamin D is the most effective among deficient populations but in most of the trials the primary level of Vitamin D was not reported, or there was an overlap of Vitamin D's effect with genetic polymorphism resulting in different results among different populations. It should not be forgotten that using Vitamin D as a preventive agent could be even more important than a curative agent and therefore studies among healthy individuals who are at high risk for TB need to be designed to see if Vitamin D can help to prevent TB.

## CONCLUSION AND FUTURE PERSPECTIVE

---

The relationship between Vitamin D and the respiratory system remains inconclusive. It is important to remember Vitamin D's effect beyond bone and calcium metabolism, but it would be immature to strictly point out a role for Vitamin D and accept it as a certain treatment for the mentioned diseases. Larger clinical trials and more comparable data are needed to put a closure on Vitamin D's association with different diseases. In either case, since there is a strong chance that this association really does exist and also Vitamin D deficiency is an epidemic all over the world, it is extremely important and recommended to prevent, diagnose and treat Vitamin D deficiency. Due to the great possibility of genetic involvement in Vitamin D's effect on respiratory disease and the high prevalence of Vitamin D deficiency in Iran, it is suggested to conduct clinical trials among the Iranian people and evaluate the efficacy of Vitamin D. The results may be different from those conducted in other populations. Health providers of the countries should take precautions to encourage people to spend more time in the sunlight and if necessary start fortifying food with Vitamin D. It also seems important to increase people's knowledge of how they can require Vitamin D and what the unhealthy consequences of Vitamin D deficiency are, because unlike usual vitamins which are believed to be obtained by a normal diet, Vitamin D's food source may not be that

much abundant. Taken together, there are many studies that significantly showed the relation between Vitamin D deficiency and many diseases, however in some cases, the administration of Vitamin D could result in a better outcome, but for now and then there is limited number of thorough and conclusive studies showing the effect of Vitamin D supplementation on the outcome of diseases. If the role of Vitamin D on the diseases could be proved, a simple treatment of Vitamin D deficiency could solve many of the respiratory problems we are dealing with better outcome, fewer adverse effects, and less expensive treatment cost.

## AUTHORS' CONTRIBUTION

---

Mohammad esmail-Hejazi: Data assembly and revision of the article. Faezeh. Modarresi-Ghazani: Literature search, writing the article. Taher Entezari-Maleki: Article revision, grammar revision.

## Financial support and sponsorship

Nil.

## Conflicts of interest

There are no conflicts of interest.

## Acknowledgments

---

The authors would like to thank Dr. Jafar Modarresi-Ghazani and Dr. Farshid Asiaei for their kind support.

## REFERENCES

---

1. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive Vitamin D to its active form: Potential effects on host defense. *J Immunol.* 2008;181:7090–9. [PMCID: PMC2596683] [PubMed: 18981129]
2. Roth DE, Jones AB, Prosser C, Robinson JL, Vohra S. Vitamin D receptor polymorphisms and the risk of acute lower respiratory tract infection in early childhood. *J Infect Dis.* 2008;197:676–80. [PubMed: 18266602]
3. Herr C, Greulich T, Koczulla RA, Meyer S, Zakharkina T, Branscheidt M, et al. The role of Vitamin D in pulmonary disease: COPD, asthma, infection, and cancer. *Respir Res.* 2011;12:31. [PMCID: PMC3071319] [PubMed: 21418564]
4. Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, et al. Epidemic influenza and Vitamin D. *Epidemiol Infect.* 2006;134:1129–40. [PMCID: PMC2870528] [PubMed: 16959053]
5. Abuzeid WM, Akbar NA, Zacharek MA. Vitamin D and chronic rhinitis. *Curr Opin Allergy Clin Immunol.* 2012;12:13–7. [PubMed: 22193052]
6. Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buyschaert I, et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the Vitamin D-binding gene. *Thorax.* 2010;65:215–20. [PubMed: 19996341]
7. Litonjua AA, Weiss ST. Is Vitamin D deficiency to blame for the asthma epidemic? *J Allergy Clin Immunol.* 2007;120:1031–5. [PubMed: 17919705]
8. Niruban SJ, Alagiakrishnan K, Beach J, Senthilselvan A. Association between Vitamin D and respiratory outcomes in Canadian adolescents and adults. *J Asthma.* 2015;52:653–61. [PubMed: 25563060]

9. Nnoaham KE, Clarke A. Low serum Vitamin D levels and tuberculosis: A systematic review and meta-analysis. *Int J Epidemiol.* 2008;37:113–9. [PubMed: 18245055]
10. Gibney KB, MacGregor L, Leder K, Torresi J, Marshall C, Ebeling PR, et al. Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. *Clin Infect Dis.* 2008;46:443–6. [PubMed: 18173355]
11. Masoli M, Fabian D, Holt S, Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: Executive summary of the GINA Dissemination Committee report. *Allergy.* 2004;59:469–78. [PubMed: 15080825]
12. Dixon AE, Holguin F, Sood A, Salome CM, Pratley RE, Beuther DA, et al. An official American Thoracic Society Workshop report: Obesity and asthma. *Proc Am Thorac Soc.* 2010;7:325–35. [PubMed: 20844291]
13. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of Vitamin D in obesity. *Am J Clin Nutr.* 2000;72:690–3. [PubMed: 10966885]
14. Celedón JC, Sredl D, Weiss ST, Pisarski M, Wakefield D, Cloutier M. Ethnicity and skin test reactivity to aeroallergens among asthmatic children in Connecticut. *Chest.* 2004;125:85–92. [PubMed: 14718425]
15. Rajakumar K, Fernstrom JD, Janosky JE, Greenspan SL. Vitamin D insufficiency in preadolescent African-American children. *Clin Pediatr (Phila)* 2005;44:683–92. [PubMed: 16211192]
16. Keating P, Munim A, Hartmann JX. Effect of Vitamin D on T-helper type 9 polarized human memory cells in chronic persistent asthma. *Ann Allergy Asthma Immunol.* 2014;112:154–62. [PubMed: 24468256]
17. Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. *J Clin Invest.* 2006;116:146–55. [PMCID: PMC1307558] [PubMed: 16341266]
18. Banerjee A, Damera G, Bhandare R, Gu S, Lopez-Boado Y, Panettieri R, Jr, et al. Vitamin D and glucocorticoids differentially modulate chemokine expression in human airway smooth muscle cells. *Br J Pharmacol.* 2008;155:84–92. [PMCID: PMC2440089] [PubMed: 18552877]
19. Chambers ES, Nanzer AM, Pfeffer PE, Richards DF, Timms PM, Martineau AR, et al. Distinct endotypes of steroid-resistant asthma characterized by IL-17A<sup>high</sup> and IFN- $\gamma$ <sup>high</sup> immunophenotypes: Potential benefits of calcitriol. *J Allergy Clin Immunol.* 2015 pii: S0091-674900165-7. [PMCID: PMC4559139]
20. Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: Vitamin D-mediated human antimicrobial activity against *Mycobacterium tuberculosis* is dependent on the induction of cathelicidin. *J Immunol.* 2007;179:2060–3. [PubMed: 17675463]
21. Bossé Y, Maghni K, Hudson TJ. 1 $\alpha$ , 25-dihydroxy-Vitamin D<sub>3</sub> stimulation of bronchial smooth muscle cells induces autocrine, contractility, and remodeling processes. *Physiol Genomics.* 2007;29:161–8. [PubMed: 17213369]
22. Song Y, Qi H, Wu C. Effect of 1,25-(OH)<sub>2</sub>D<sub>3</sub> (a vitamin D analogue) on passively sensitized human airway smooth muscle cells. *Respirology.* 2007;12:486–94. [PubMed: 17587413]
23. Kho AT, Sharma S, Qiu W, Gaedigk R, Klanderman B, Niu S, et al. Vitamin D related genes in lung development and asthma pathogenesis. *BMC Med Genomics.* 2013;6:47. [PMCID: PMC4228235] [PubMed: 24188128]
24. Sundar IK, Hwang JW, Wu S, Sun J, Rahman I. Deletion of Vitamin D receptor leads to premature emphysema/COPD by increased matrix metalloproteinases and lymphoid aggregates formation. *Biochem*



Biophys Res Commun. 2011;406:127–33. [PMCID: PMC3049841] [PubMed: 21300024]

25. de Groot JC, van Roon EN, Storm H, Veeger NJ, Zwinderman AH, Hiemstra PS, et al. Vitamin D reduces eosinophilic airway inflammation in nonatopic asthma. *J Allergy Clin Immunol.* 2015;135:670–5.e3. [PubMed: 25617224]

26. Gern JE, Lemanske RF, Jr, Busse WW. Early life origins of asthma. *J Clin Invest.* 1999;104:837–43. [PMCID: PMC408565] [PubMed: 10510321]

27. Warner JA, Jones CA, Jones AC, Warner JO. Prenatal origins of allergic disease. *J Allergy Clin Immunol.* 2000;105:S493–8. [PubMed: 10669530]

28. Martindale S, McNeill G, Devereux G, Campbell D, Russell G, Seaton A. Antioxidant intake in pregnancy in relation to wheeze and eczema in the first two years of life. *Am J Respir Crit Care Med.* 2005;171:121–8. [PubMed: 15531754]

29. Litonjua AA, Rifas-Shiman SL, Ly NP, Tantisira KG, Rich-Edwards JW, Camargo CA, Jr, et al. Maternal antioxidant intake in pregnancy and wheezing illnesses in children at 2 y of age. *Am J Clin Nutr.* 2006;84:903–11. [PMCID: PMC1994925] [PubMed: 17023719]

30. Erkkola M, Kaila M, Nwaru BI, Kronberg-Kippilä C, Ahonen S, Nevalainen J, et al. Maternal Vitamin D intake during pregnancy is inversely associated with asthma and allergic rhinitis in 5-year-old children. *Clin Exp Allergy.* 2009;39:875–82. [PubMed: 19522996]

31. Devereux G, Turner SW, Craig LC, McNeill G, Martindale S, Harbour PJ, et al. Low maternal Vitamin E intake during pregnancy is associated with asthma in 5-year-old children. *Am J Respir Crit Care Med.* 2006;174:499–507. [PubMed: 16763215]

32. Devereux G, Litonjua AA, Turner SW, Craig LC, McNeill G, Martindale S, et al. Maternal Vitamin D intake during pregnancy and early childhood wheezing. *Am J Clin Nutr.* 2007;85:853–9. [PubMed: 17344509]

33. Willers SM, Devereux G, Craig LC, McNeill G, Wijga AH, Abou El-Magd W, et al. Maternal food consumption during pregnancy and asthma, respiratory and atopic symptoms in 5-year-old children. *Thorax.* 2007;62:773–9. [PMCID: PMC2117307] [PubMed: 17389754]

34. Miller DR, Turner SW, Spiteri-Cornish D, Scaife AR, Danielian PJ, Devereux GS, et al. Maternal Vitamin D and E intakes during early pregnancy are associated with airway epithelial cell responses in neonates. *Clin Exp Allergy.* 2015;45:920–7. [PubMed: 25616026]

35. Grubczak K, Lipinska D, Eljaszewicz A, Singh P, Radzikowska U, Miklasz P, et al. Vitamin D3 treatment decreases frequencies of CD16-positive and TNF- $\alpha$ -secreting monocytes in asthmatic patients. *Int Arch Allergy Immunol.* 2015;166:170–6. [PubMed: 25872112]

36. Drozdenko G, Heine G, Worm M. Oral Vitamin D increases the frequencies of CD38+ human B cells and ameliorates IL-17-producing T cells. *Exp Dermatol.* 2014;23:107–12. [PubMed: 24313624]

37. Hansen S, Maslova E, Strøm M, Linneberg A, Halldorsson TI, Granström C, et al. The long-term programming effect of maternal 25-hydroxyvitamin D in pregnancy on allergic airway disease and lung function in offspring after 20 to 25 years of follow-up. *J Allergy Clin Immunol.* 2015;136:169–76.e2. [PubMed: 25649083]

38. Chiu CY, Huang SY, Peng YC, Tsai MH, Hua MC, Yao TC, et al. Maternal Vitamin D levels are inversely related to allergic sensitization and atopic diseases in early childhood. *Pediatr Allergy Immunol.* 2015;26:337–43. [PubMed: 25847488]

39. Leung TF, Wang SS, Tang MF, Kong AP, Sy HY, Hon KL, et al. Childhood asthma and spirometric indices are associated with polymorphic markers of two Vitamin D 25-hydroxylase genes. *Pediatr Allergy Immunol.* 2015;26:375–82. [PubMed: 25845986]
40. Maguire JL, Birken CS, Loeb MB, Mamdani M, Thorpe K, Hoch JS, et al. DO IT Trial: Vitamin D outcomes and interventions in toddlers – A TARGet Kids! randomized controlled trial. *BMC Pediatr.* 2014;14:37. [PMCID: PMC3942179] [PubMed: 24506910]
41. Bose S, Breysse PN, McCormack MC, Hansel NN, Rusher RR, Matsui E, et al. Outdoor exposure and Vitamin D levels in urban children with asthma. *Nutr J.* 2013;12:81. [PMCID: PMC3686669] [PubMed: 23758744]
42. Bener A, Ehlayel MS, Tulic MK, Hamid Q. Vitamin D deficiency as a strong predictor of asthma in children. *Int Arch Allergy Immunol.* 2012;157:168–75. [PubMed: 21986034]
43. Brehm JM, Schuemann B, Fuhlbrigge AL, Hollis BW, Strunk RC, Zeiger RS, et al. Serum Vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. *J Allergy Clin Immunol.* 2010;126:52–8.e5. [PMCID: PMC2902692] [PubMed: 20538327]
44. Brehm JM, Celedón JC, Soto-Quiros ME, Avila L, Hunninghake GM, Forno E, et al. Serum Vitamin D levels and markers of severity of childhood asthma in Costa Rica. *Am J Respir Crit Care Med.* 2009;179:765–71. [PMCID: PMC2675563] [PubMed: 19179486]
45. Yadav M, Mittal K. Effect of Vitamin D supplementation on moderate to severe bronchial asthma. *Indian J Pediatr.* 2014;81:650–4. [PubMed: 24193954]
46. Sutherland ER, Goleva E, Jackson LP, Stevens AD, Leung DY. Vitamin D levels, lung function, and steroid response in adult asthma. *Am J Respir Crit Care Med.* 2010;181:699–704. [PMCID: PMC2868500] [PubMed: 20075384]
47. Castro M, King TS, Kunselman SJ, Cabana MD, Denlinger L, Holguin F, et al. Effect of Vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower Vitamin D levels: The VIDA randomized clinical trial. *JAMA.* 2014;311:2083–91. [PMCID: PMC4217655] [PubMed: 24838406]
48. Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. *Chest.* 2005;128:3792–8. [PubMed: 16354847]
49. Arshi S, Fallahpour M, Nabavi M, Bemanian MH, Javad-Mousavi SA, Nojomi M, et al. The effects of Vitamin D supplementation on airway functions in mild to moderate persistent asthma. *Ann Allergy Asthma Immunol.* 2014;113:404–9. [PubMed: 25091714]
50. Varney VA, Evans J, Bansal AS. Successful treatment of reactive airways dysfunction syndrome by high-dose Vitamin D. *J Asthma Allergy.* 2011;4:87–91. [PMCID: PMC3196486] [PubMed: 22034572]
51. Cheng HM, Kim S, Park GH, Chang SE, Bang S, Won CH, et al. Low Vitamin D levels are associated with atopic dermatitis, but not allergic rhinitis, asthma, or IgE sensitization, in the adult Korean population. *J Allergy Clin Immunol.* 2014;133:1048–55. [PubMed: 24388009]
52. Martineau AR, MacLaughlin BD, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, et al. Double-blind randomised placebo-controlled trial of bolus-dose Vitamin D3 supplementation in adults with asthma (ViDiAs) *Thorax.* 2015;70:451–7. [PubMed: 25724847]
53. Brody H. Chronic obstructive pulmonary disease. *Nature.* 2012;489:S1. [PubMed: 23013707]
54. Vogelmeier C, Koczulla R, Fehrenbach H, Bals R. Pathogenesis of chronic obstructive pulmonary disease. *Internist (Berl)* 2006;47:885–6. 888-90, 892-4. [PubMed: 16845536]

55. Persson LJ, Aanerud M, Hiemstra PS, Hardie JA, Bakke PS, Eagan TM. Chronic obstructive pulmonary disease is associated with low levels of Vitamin D. *PLoS One*. 2012;7:e38934. [PMCID: PMC3380863] [PubMed: 22737223]
56. Crane-Godreau MA, Black CC, Giustini AJ, Dechen T, Ryu J, Jukosky JA, et al. Modeling the influence of Vitamin D deficiency on cigarette smoke-induced emphysema. *Front Physiol*. 2013;4:132. [PMCID: PMC3679474] [PubMed: 23781205]
57. Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: Oxidative stress, protease-antiprotease imbalance, and inflammation. *Int J Chron Obstruct Pulmon Dis*. 2011;6:413–21. [PMCID: PMC3157944] [PubMed: 21857781]
58. Stocks J, Sonnappa S. Early life influences on the development of chronic obstructive pulmonary disease. *Ther Adv Respir Dis*. 2013;7:161–73. [PMCID: PMC4107852] [PubMed: 23439689]
59. Svanes C, Sunyer J, Plana E, Dharmage S, Heinrich J, Jarvis D, et al. Early life origins of chronic obstructive pulmonary disease. *Thorax*. 2010;65:14–20. [PubMed: 19729360]
60. Nguyen M, Trubert CL, Rizk-Rabin M, Rehan VK, Besançon F, Cayre YE, et al. 1,25-Dihydroxyvitamin D<sub>3</sub> and fetal lung maturation: Immunogold detection of VDR expression in pneumocytes type II cells and effect on fructose 1,6 bisphosphatase. *J Steroid Biochem Mol Biol*. 2004;89:90:93–7. [PubMed: 15225753]
61. Nguyen TM, Guillozo H, Marin L, Tordet C, Koite S, Garabedian M. Evidence for a Vitamin D paracrine system regulating maturation of developing rat lung epithelium. *Am J Physiol*. 1996;271:L392–9. [PubMed: 8843787]
62. Uh ST, Koo SM, Kim YK, Kim KU, Park SW, Jang AS, et al. Inhibition of vitamin d receptor translocation by cigarette smoking extracts. *Tuberc Respir Dis (Seoul)* 2012;73:258–65. [PMCID: PMC3517944] [PubMed: 23236317]
63. Hopkinson NS, Li KW, Kehoe A, Humphries SE, Roughton M, Moxham J, et al. Vitamin D receptor genotypes influence quadriceps strength in chronic obstructive pulmonary disease. *Am J Clin Nutr*. 2008;87:385–90. [PubMed: 18258629]
64. Janssens W, Decramer M, Mathieu C, Korf H. Vitamin D and chronic obstructive pulmonary disease: Hype or reality? *Lancet Respir Med*. 2013;1:804–12. [PubMed: 24461760]
65. Førli L, Halse J, Haug E, Bjørtuft Ø, Vatn M, Kofstad J, et al. Vitamin D deficiency, bone mineral density and weight in patients with advanced pulmonary disease. *J Intern Med*. 2004;256:56–62. [PubMed: 15189366]
66. Janssens W, Mathieu C, Boonen S, Decramer M. Vitamin D deficiency and chronic obstructive pulmonary disease: A vicious circle. *Vitam Horm*. 2011;86:379–99. [PubMed: 21419281]
67. Monadi M, Heidari B, Asgharpour M, Firouzbahi A, Monadi M, Ghazi Mirsaied MA. Relationship between serum Vitamin D and forced expiratory volume in patients with chronic obstructive pulmonary disease (COPD) *Caspian J Intern Med*. 2012;3:451–5. [PMCID: PMC3755852] [PubMed: 24009913]
68. Zendedel A, Gholami M, Anbari K, Ghanadi K, Bachari EC, Azargon A. Effects of Vitamin D intake on FEV1 and COPD exacerbation: A randomized clinical trial study. *Glob J Health Sci*. 2015;7:243–8. [PMCID: PMC4796438] [PubMed: 25946929]
69. Afzal S, Lange P, Bojesen SE, Freiberg JJ, Nordestgaard BG. Plasma 25-hydroxyvitamin D, lung function and risk of chronic obstructive pulmonary disease. *Thorax*. 2014;69:24–31. [PubMed: 23908128]

70. Martineau AR, James WY, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): A multicentre, double-blind, randomised controlled trial. *Lancet Respir Med*. 2015;3:120–30. [PubMed: 25476069]
71. Holmgaard DB, Mygind LH, Titlestad IL, Madsen H, Fruekilde PB, Pedersen SS, et al. Serum Vitamin D in patients with chronic obstructive lung disease does not correlate with mortality-results from a 10-year prospective cohort study. *PLoS One*. 2013;8:e53670. [PMCID: PMC3544862] [PubMed: 23341971]
72. Kunisaki KM, Niewoehner DE, Connett JE. Severe Vitamin D deficiency: A biomarker of exacerbation risk?: A reply to Heulens. *Am J Respir Crit Care Med*. 2013;187:215–6. [PMCID: PMC3570652] [PubMed: 23441318]
73. Lehouck A, Mathieu C, Carremans C, Baeke F, Verhaegen J, Van Eldere J, et al. High doses of Vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: A randomized trial. *Ann Intern Med*. 2012;156:105–14. [PubMed: 22250141]
74. Bjerck SM, Edgington BD, Rector TS, Kunisaki KM. Supplemental Vitamin D and physical performance in COPD: A pilot randomized trial. *Int J Chron Obstruct Pulmon Dis*. 2013;8:97–104. [PMCID: PMC3575124] [PubMed: 23430315]
75. Ferrari M, Schenk K, Papadopoulou C, Ferrari P, Dalle Carbonare L, Bertoldo F. Serum 25-hydroxy Vitamin D and exercise capacity in COPD. *Thorax*. 2011;66:544–5. [PubMed: 21037271]
76. Hornikx M, Van Remoortel H, Lehouck A, Mathieu C, Maes K, Gayan-Ramirez G, et al. Vitamin D supplementation during rehabilitation in COPD: A secondary analysis of a randomized trial. *Respir Res*. 2012;13:84. [PMCID: PMC3493348] [PubMed: 23006613]
77. Banerjee A, Panettieri R., Jr Vitamin D modulates airway smooth muscle function in COPD. *Curr Opin Pharmacol*. 2012;12:266–74. [PubMed: 22365730]
78. Romme EA, Smeenk FW, Rutten EP, Wouters EF. Osteoporosis in chronic obstructive pulmonary disease. *Expert Rev Respir Med*. 2013;7:397–410. [PubMed: 23952337]
79. Duckers JM, Evans BA, Fraser WD, Stone MD, Bolton CE, Shale DJ. Low bone mineral density in men with chronic obstructive pulmonary disease. *Respir Res*. 2011;12:101. [PMCID: PMC3161864] [PubMed: 21812978]
80. Franco CB, Paz-Filho G, Gomes PE, Nascimento VB, Kulak CA, Boguszewski CL, et al. Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of Vitamin D. *Osteoporos Int*. 2009;20:1881–7. [PubMed: 19300892]
81. Romme EA, Rutten EP, Smeenk FW, Spruit MA, Menheere PP, Wouters EF. Vitamin D status is associated with bone mineral density and functional exercise capacity in patients with chronic obstructive pulmonary disease. *Ann Med*. 2013;45:91–6. [PubMed: 22462562]
82. Skaaby T, Husemoen LL, Thuesen BH, Pisinger C, Jørgensen T, Fenger RV, et al. Vitamin D status and chronic obstructive pulmonary disease: A prospective general population study. *PLoS One*. 2014;9:e90654. [PMCID: PMC3942472] [PubMed: 24594696]
83. Chishimba L, Thickett DR, Stockley RA, Wood AM. The vitamin D axis in the lung: A key role for Vitamin D-binding protein. *Thorax*. 2010;65:456–62. [PubMed: 20435872]
84. Metcalf JP, Thompson AB, Gossman GL, Nelson KJ, Koyama S, Rennard SI, et al. Gc-globulin functions as a chemoattractant in the lower respiratory tract. A potential mechanism for lung neutrophil recruitment in cigarette smokers. *Am Rev Respir Dis*. 1991;143:844–9. [PubMed: 2008995]

85. DiMartino SJ, Shah AB, Trujillo G, Kew RR. Elastase controls the binding of the Vitamin D-binding protein (Gc-globulin) to neutrophils: A potential role in the regulation of C5a co-chemotactic activity. *J Immunol.* 2001;166:2688–94. [PubMed: 11160333]
86. Salamon H, Bruiners N, Lakehal K, Shi L, Ravi J, Yamaguchi KD, et al. Cutting edge: Vitamin D regulates lipid metabolism in *Mycobacterium tuberculosis* infection. *J Immunol.* 2014;193:30–4. [PMCID: PMC4073889] [PubMed: 24899504]
87. Lalvani A, Connell DW. Dissecting the immunological, antimicrobial and clinical effects of Vitamin D therapy in tuberculosis. *Pathog Glob Health.* 2012;106:378–9. [PMCID: PMC4001618] [PubMed: 23265607]
88. Desai NS, Tukvadze N, Frediani JK, Kipiani M, Sanikidze E, Nichols MM, et al. Effects of sunlight and diet on Vitamin D status of pulmonary tuberculosis patients in Tbilisi, Georgia. *Nutrition.* 2012;28:362–6. [PMCID: PMC3303957] [PubMed: 22304856]
89. Selvaraj P. Vitamin D, Vitamin D receptor, and cathelicidin in the treatment of tuberculosis. *Vitam Horm.* 2011;86:307–25. [PubMed: 21419277]
90. Dini C, Bianchi A. The potential role of Vitamin D for prevention and treatment of tuberculosis and infectious diseases. *Ann Ist Super Sanita.* 2012;48:319–27. [PubMed: 23007057]
91. Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF, et al. Vitamin D-directed rheostatic regulation of monocyte antibacterial responses. *J Immunol.* 2009;182:4289–95. [PMCID: PMC2683618] [PubMed: 19299728]
92. Chocano-Bedoya P, Ronnenberg AG. Vitamin D and tuberculosis. *Nutr Rev.* 2009;67:289–93. [PubMed: 19386033]
93. Fabri M, Stenger S, Shin DM, Yuk JM, Liu PT, Realegeno S, et al. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. *Sci Transl Med.* 2011;3:104ra102. [PMCID: PMC3269210]
94. Overbergh L, Decallonne B, Waer M, Rutgeerts O, Valckx D, Casteels KM, et al. 1 $\alpha$ , 25-dihydroxyvitamin D<sub>3</sub> induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543) Diabetes. 2000;49:1301–7. [PubMed: 10923629]
95. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1 $\alpha$ , 25-Dihydroxyvitamin d<sub>3</sub> has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. *J Immunol.* 2001;167:4974–80. [PubMed: 11673504]
96. Lin PL, Flynn JL. Understanding latent tuberculosis: A moving target. *J Immunol.* 2010;185:15–22. [PMCID: PMC3311959] [PubMed: 20562268]
97. Nnoaham KE, Clarke A. Low serum Vitamin D levels and tuberculosis: A systematic review and meta-analysis. *Int J Epidemiol.* 2008;37:113–9. [PubMed: 18245055]
98. Nursyam EW, Amin Z, Rumende CM. The effect of Vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. *Acta Med Indones.* 2006;38:3–5. [PubMed: 16479024]
99. Wejse C, Gomes VF, Rabna P, Gustafson P, Aaby P, Lisse IM, et al. Vitamin D as supplementary treatment for tuberculosis: A double-blind, randomized, placebo-controlled trial. *Am J Respir Crit Care Med.* 2009;179:843–50. [PubMed: 19179490]
100. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, et al. High-dose Vitamin D (3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: A double-blind

randomised controlled trial. *Lancet*. 2011;377:242–50. [PMCID: PMC4176755] [PubMed: 21215445]

101. Salahuddin N, Ali F, Hasan Z, Rao N, Aqeel M, Mahmood F. Vitamin D accelerates clinical recovery from tuberculosis: Results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of Vitamin D supplementation in patients with pulmonary tuberculosis' *BMC Infect Dis*. 2013;13:22. [PMCID: PMC3556334] [PubMed: 23331510]

102. Daley P, Jagannathan V, John KR, Sarojini J, Latha A, Vieth R, et al. Adjunctive Vitamin D for treatment of active tuberculosis in India: A randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis*. 2015;15:528–34. [PubMed: 25863562]

103. Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, Hall BM, et al. A single dose of Vitamin D enhances immunity to mycobacteria. *Am J Respir Crit Care Med*. 2007;176:208–13. [PubMed: 17463418]

104. Holick MF. Vitamin D status: Measurement, interpretation, and clinical application. *Ann Epidemiol*. 2009;19:73–8. [PMCID: PMC2665033] [PubMed: 18329892]

105. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of Vitamin D deficiency: An endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2011;96:1911–30. [PubMed: 21646368]

106. Vieth R. Vitamin D nutrient to treat TB begs the prevention question. *Lancet*. 2011;377:189–90. [PubMed: 21215444]

107. Douglas AS, Strachan DP, Maxwell JD. Seasonality of tuberculosis: The reverse of other respiratory diseases in the UK. *Thorax*. 1996;51:944–6. [PMCID: PMC472621] [PubMed: 8984709]

108. Martineau AR, Nhamoyebonde S, Oni T, Rangaka MX, Marais S, Bangani N, et al. Reciprocal seasonal variation in Vitamin D status and tuberculosis notifications in Cape Town, South Africa. *Proc Natl Acad Sci U S A*. 2011;108:19013–7. [PMCID: PMC3223428] [PubMed: 22025704]

109. Schaaf HS, Nel ED, Beyers N, Gie RP, Scott F, Donald PR. A decade of experience with *Mycobacterium tuberculosis* culture from children: A seasonal influence on incidence of childhood tuberculosis. *Tuber Lung Dis*. 1996;77:43–6. [PubMed: 8733413]

110. Thorpe LE, Laserson K, Cookson S, Mills W, Field K, Koppaka VR, et al. Infectious tuberculosis among newly arrived refugees in the United States. *N Engl J Med*. 2004;350:2105–6. [PubMed: 15141058]

111. Strachan DP, Powell KJ, Thaker A, Millard FJ, Maxwell JD. Vegetarian diet as a risk factor for tuberculosis in immigrant South London Asians. *Thorax*. 1995;50:175–80. [PMCID: PMC473919] [PubMed: 7701458]

112. Williams B, Williams AJ, Anderson ST. Vitamin D deficiency and insufficiency in children with tuberculosis. *Pediatr Infect Dis J*. 2008;27:941–2. [PubMed: 18776821]

113. Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A, et al. Influence of Vitamin D deficiency and Vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in West London: A case-control study. *Lancet*. 2000;355:618–21. [PubMed: 10696983]

114. Bellamy R, Ruwende C, Corrah T, McAdam KP, Thursz M, Whittle HC, et al. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the Vitamin D receptor gene. *J Infect Dis*. 1999;179:721–4. [PubMed: 9952386]

115. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K, et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. *Proc Natl Acad Sci U S A*.

2012;109:15449–54. [PMCID: PMC3458393] [PubMed: 22949664]

116. Alyasin S, Momen T, Kashef S, Alipour A, Amin R. The relationship between serum 25 hydroxy Vitamin D levels and asthma in children. *Allergy Asthma Immunol Res.* 2011;3:251–5.

[PMCID: PMC3178823] [PubMed: 21966605]

117. Quint JK, Wedzicha JA. Is Vitamin D deficiency important in the natural history of COPD? *Thorax.* 2010;65:192–4. [PubMed: 20335285]

118. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of Vitamin D receptor polymorphisms. *Gene.* 2004;338:143–56. [PubMed: 15315818]

119. Gibney KB, MacGregor L, Leder K, Torresi J, Marshall C, Ebeling PR, et al. Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. *Clin Infect Dis.* 2008;46:443–6. [PubMed: 18173355]

---

Articles from Journal of Research in Pharmacy Practice are provided here courtesy of **Medknow Publications**